NASDAQ: PSTV
Plus Therapeutics Inc Stock Ownership - Who owns Plus Therapeutics?

Insider buying vs selling

Have Plus Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Andrew John Hugh Macintyre SimsChief Financial Officer2025-11-0420,000$0.51
$10.20kBuy
Robert P. LenkDirector2025-08-22110,000$0.49
$53.79kBuy

1 of 1

PSTV insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when PSTV insiders and whales buy or sell their stock.

PSTV Shareholders

What type of owners hold Plus Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Kian Thiam Lim5.38%7,400,000$5.06MInsider
Bank Sa Swissquote3.88%5,328,229$3.64MInsider
Ag Postfinance3.31%4,543,086$3.11MInsider
Olympus Corp2.92%4,013,043$2.74MInsider
Vanguard Group Inc1.05%1,446,827$989.63kInstitution
Altium Capital Management LLC0.67%918,914$628.54kInstitution
Geode Capital Management LLC0.59%813,250$556.26kInstitution
Ubs Group Ag0.45%623,874$426.73kInstitution
Blackrock Inc0.34%469,389$321.06kInstitution
Marshall G. Cox0.30%417,050$285.26kInsider

1 of 3

PSTV vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
PSTV3.79%17.25%Net BuyingNet Buying
STRO77.50%22.50%Net SellingNet Buying
THAR2.30%15.90%Net Buying
SPRB13.84%86.16%Net SellingNet Selling
MGNX65.80%34.20%Net Buying

Plus Therapeutics Stock Ownership FAQ

Who owns Plus Therapeutics?

Plus Therapeutics (NASDAQ: PSTV) is owned by 3.79% institutional shareholders, 17.25% Plus Therapeutics insiders, and 78.96% retail investors. Kian Thiam Lim is the largest individual Plus Therapeutics shareholder, owning 7.40M shares representing 5.38% of the company. Kian Thiam Lim's Plus Therapeutics shares are currently valued at $4.59M.

If you're new to stock investing, here's how to buy Plus Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.